A very low carbohydrate, high-fat diet called the ketogenic diet may improve the effectiveness of an emerging class of cancer drugs, according to a study in mice by investigators at Weill Cornell Medicine, Columbia University Irving Medical Center and NewYork-Presbyterian.

Dr. Jordan Orange has been appointed pediatrician-in-chief of NewYork-Presbyterian Morgan Stanley Children’s Hospital and chair of pediatrics at Columbia University Vagelos College of Physicians and Surgeons, effective July 1. Dr. Orange joins from Baylor College of Medicine at Texas Children’s Hospital, where he served as professor and vice chair for research in pediatrics. He succeeds Dr. Lawrence R. Stanberry, who has served as pediatrician-in-chief and chair of pediatrics since 2008.

Growing miniature tumors from patient’s cells in the laboratory may help scientists personalize treatments for those with a rare form of prostate cancer, according a study by Weill Cornell Medicine and NewYork-Presbyterian scientists.

Many cases of early-stage kidney cancer can be treated with a relatively new, nonsurgical procedure used to destroy tumors, a new study by a team led by Weill Cornell Medicine and NewYork-Presbyterian suggests.

Dr. Dan Landau, an assistant professor of medicine and of physiology and biophysics at Weill Cornell Medicine, and a core faculty member of the New York Genome Center, has been awarded the Pershing Square Sohn Prize for Young Investigators in Cancer Research to support his work studying cancer evolution.

NewYork-Presbyterian Hudson Valley Hospital’s Cheryl R. Lindenbaum Comprehensive Cancer Center brings the expertise and innovation of one of New York’s three NCI-designated Comprehensive Cancer Centers to patients in the Hudson Valley region, thanks to its collaboration with NewYork-Presbyterian/Columbia University Irving Medical Center (NYP/CUIMC) and ColumbiaDoctors, its faculty medical practice

Dr. Laura Riley, a renowned obstetrician who specializes in obstetric infectious disease, has been appointed chair of the Department of Obstetrics and Gynecology at Weill Cornell Medicine and Obstetrician and Gynecologist-in-chief at NewYork-Presbyterian/Weill Cornell Medical Center, effective Oct. 1.

Conventional wisdom suggests that a high level of the protein prostate specific antigen (PSA) in men with prostate cancer means a poor prognosis. However, this may not always be the case in men with a particular subtype of prostate cancer, according to a new study from Weill Cornell Medicine and NewYork-Presbyterian researchers.